bempedoic acid
- Generic Name
- bempedoic acid
- Brand Names
- Nexletol, Nexlizet, Nilemdo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H36O5
- CAS Number
- 738606-46-7
- Unique Ingredient Identifier
- 1EJ6Z6Q368
- Background
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed...
- Indication
作为饮食和最大耐受性他汀类药物治疗的辅助药物，用于治疗患有杂合子家族性高胆固醇血症或需要额外降低LDL-C的动脉粥样硬化性心血管疾病的成人。
- Associated Conditions
- Atherosclerotic Cardiovascular Diseases, Heterozygous Familial Hypercholesterolemia (HeFH)
- Associated Therapies
- -
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 779
- Registration Number
- NCT02991118
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 345
- Registration Number
- NCT02988115
- Locations
- 🇺🇸
Site 2, Dallas, Texas, United States
🇺🇸Site 1, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath